Navigation Links
PharmaDirections Announces Appointment of Dr. Bruce Rehlaender as Principal, Formulation Development
Date:1/22/2013

Cary, NC (PRWEB) January 22, 2013

Dr. Bruce Rehlaender has been appointed a Principal, Formulation Development at PharmaDirections. He will be based in the Portland, Oregon area and will have proximity to a growing market in early stage drug development. The appointment is a reflection of the invaluable contributions he has made over the past 6 years to the virtual biotech companies served by PharmaDirections.

Dr. Rehlaender joined PharmaDirections in 2007 as the Director, Formulation Development. In that capacity, he led multi-disciplinary teams of product development scientists who developed novel drug products using specialized expertise in biopharmaceutics, pharmacokinetics and formulation development.

There have been many significant achievements in his tenure, but we only have room for a few. Dr. Rehlaender led the development of the tri-layer, sustained release tablet formulations for Orexigen’s Contrave; that NDA was filed in 2010. He led many In-Silico PK Modeling programs that resulted in establishing optimum release patterns for over 12 unique client programs. He is the inventor on 5 patents that were developed for PharmaDirections’ clients was responsible for the formulation development efforts in over 20 unique client programs.

Over his 25 year industrial career, Dr. Rehlaender has developed his expertise in biopharmaceutics and formulation development with special expertise in challenges such as poorly soluble drugs, unstable compounds, and sophisticated controlled release patterns. He has extensive experience in developing parenteral products; oral tablets, capsules, and liquids; nebulizer products; dry powder inhalers; and topicals. His experience covers product processing from bench top to commercial manufacturing where he has developed processes for emulsification, powder milling, steam sterilization; aseptic manufacture; lyophilization; and separation of proteins.

Dr. Rehlaender's analytical expertise is primarily in solids characterization, including differential scanning calorimetry, thermogravimetric analysis, dynamic vapor sorption, powder flow measurement, and particle sizing using laser diffraction, photon correlation spectroscopy; electrozone sensing, and light obscuration.

About PharmaDirections

PharmaDirections is a consulting and project management company with a unique approach to managing preclinical, CMC and regulatory affairs programs. We provide strategic planning then oversee and direct pharmaceutical contract research using our own scientific experts and project managers. We are a comprehensive resource for virtual pharmaceutical and biotech companies who need to stay lean by outsourcing their R&D activities.

http://www.PharmaDirections.com

Read the full story at http://www.prweb.com/releases/2013/1/prweb10341546.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. PharmaDirections Succeeds Through its Client’s Successes: Cortendo Receives Positive Orphan Drug Opinion from EMA for NormoCort for Cushing’s Disease
2. NSG Announces New Quartz Micro Flow Channel
3. Amgen Announces Webcast of 2012 Fourth Quarter and Full Year Financial Results
4. Inflamax Research announces the launch of its Mobile Environmental Exposure Chamber™ for conduct of Allergy & Asthma Trials
5. ASAE Foundation Announces Winners of the Innovation Grant Program
6. LATISTA Announces Next-Generation iPad App 2.0 for Construction with Industry Leading Innovations
7. GlycoCheck Announces Partnership in the United States with Vascular Health Sciences
8. Wysebridge Patent Bar Review Announces the Launch of News Blog
9. Convoy Therapeutics Announces the Relaunch of Their Interactive Website
10. BroadData Conferencing Announces Enhanced International Audio Conference Call Capabilities
11. MakeSigns.com Announces New Tri-Fold Scientific Poster Service
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2020)... ... May 19, 2020 , ... Eaton Square is pleased to announce its growth ... a biotechnology and medical technology-focused strategy and M&A advisory firm. , This is an ... linking US and Asia Pacific healthcare innovators with capital and investors. , Popper and ...
(Date:5/15/2020)... FREDERICK, Md. (PRWEB) , ... ... ... a leading supplier of human mesenchymal stem/stromal cell (hMSC) working cell banks ... RoosterCollect™-EV-CC to enable streamlined and multi-format collection of hMSC-derived extracellular vesicles ...
(Date:5/15/2020)... ... May 14, 2020 , ... This new service offers clients a way ... questions answered quickly as the need arises. Lachman’s OnCall SMEs have extensive knowledge of ... rates. , Lachman OnCall™ SMEs are available normal business hours Monday through Friday ...
(Date:5/14/2020)... ... May 12, 2020 , ... DuPont Nutrition & ... partner for all personal care ingredients in Russia and Belarus. Beginning May 1, ... portfolio for personal care. , The GENENCARE®OSMS product line contains a ...
Breaking Biology Technology:
(Date:5/30/2020)... ... May 29, 2020 , ... eInfochips, a leading provider ... collaborated with EchoNous Inc. to develop the cloud-based connected health KOSMOS platform that ... which has been clinically tested versus expert measurements, yielding improved results in precision ...
(Date:5/28/2020)... ... May 28, 2020 , ... DuPont ... liquefaction: AMYLEX® 6T. The innovative enzyme enables numerous business gains for breweries ... locally-sourced raw materials, improve productivity, maximize yield, ensure consistent quality and ultimately ...
(Date:5/25/2020)... ... ... Oxford Nanopore Technologies is in advanced development of a new generation of ... , The LamPORE assay is designed to be rapid, low cost, and scalable ... samples. Hardware and reagents sit outside current, squeezed supply chains for other molecular ...
Breaking Biology News(10 mins):